SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Phaarmasia informs about disclosure

11 Nov 2022 Evaluate
Phaarmasia has informed that the Company is in receipt of the initial public announcement dated 11th November, 2022 made by Saffron Capital Advisors, Manager to the Offer, on behalf of Maneesh Pharmaceuticals, representing the Promoter Group of Phaarmasia (Company) in accordance with Regulation 8 of the SEBI (Delisting of Equity Shares) Regulations 2021, as amended, expressing the intention to voluntary delist the equity shares of the Company (Initial Public Announcement or IPA.

The above information is a part of company’s filings submitted to BSE.

Phaarmasia Share Price

113.80 1.80 (1.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×